NCT01790633 - Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests | Biotech Hunter

Enrollment

327

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

October 31, 2013

Conditions

HIVHepatitis BHepatitis CCarcinoma, HepatocellularAIDS

Interventions

OTHER

ELISA

Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).

OTHER

Rapid Test

A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.

Trial Locations (1)

75011

Consultation d'Accueil, de Soins et d'Orientation (CASO) de Médecins du Monde (MDM), Paris